Glaukos Corporation (GKOS) Stock Analysis
Healthcare · Medical Devices
Wait for pullback to $119.16. At $124.26 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $119.16 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 8.2%; Expensive valuation.
Glaukos Corporation is a ophthalmic medical device and pharmaceutical company specializing in novel therapies for glaucoma, corneal health, and retinal disease. It earns revenue primarily from sales of the iStent and iDose trabecular micro-bypass devices and corneal health... Read more
Wait for pullback to $119.16. At $124.26 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $119.16 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 8.2%; Expensive valuation. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 5.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 48d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-11Recent Developments — Glaukos Corporation
Latest news
- NEWS Glaukos (NYSE:GKOS) Stock Price Down 4.5% - Here's Why - MarketBeat — MarketBeat negative
- NEWS GKOS Reiterated by BTIG -- Price Target Maintained at $162 - GuruFocus — GuruFocus positive
- NEWS Stifel reiterates Glaukos stock rating on regulatory optimism - Investing.com — Investing.com positive
- NEWS Stifel reiterates Glaukos stock rating on regulatory optimism By Investing.com - Investing.com Canada — Investing.com Canada positive
- NEWS Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus - AD HOC NEWS — AD HOC NEWS positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $119.16. At $124.26 the A.R:R is 0.5:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $119.16 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Thin upside margin: 8.2%; Expensive valuation. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $134.41 (+8.2%), stop $102.21 (−21.6%), Setup A.R:R 2.0:1. Score 5.5/10, moderate confidence.
Take-profit target: $134.41 (+13.9% upside). Target $134.41 (+8.2%), stop $102.21 (−21.6%), Setup A.R:R 2.0:1. Stop-loss: $102.21.
Thin upside margin: 8.2%; Expensive valuation; Value-trap signals (2/5): Margin compression (op margin -13.2%), Material insider selling (15 sells, 0.09% of cap).
Glaukos Corporation trades at a P/E of N/A (forward 254.7). TrendMatrix value score: 3.6/10. Verdict: Buy (Wait for Entry).
21 analysts cover GKOS with a consensus score of 4.2/5. Average price target: $155.
What does Glaukos Corporation do?Glaukos Corporation is a ophthalmic medical device and pharmaceutical company specializing in novel therapies for...
Glaukos Corporation is a ophthalmic medical device and pharmaceutical company specializing in novel therapies for glaucoma, corneal health, and retinal disease. It earns revenue primarily from sales of the iStent and iDose trabecular micro-bypass devices and corneal health products in the U.S. and internationally.